Orphazyme A/S (ORPHA.CO)

DKK 1120.0

(-2.61%)

Total Assets Summary of Orphazyme A/S

Orphazyme A/S's latest annual total assets in 2023 was 19.31 Million DKK , down -66.02% from previous year.
Orphazyme A/S's latest quarterly total assets in 2024 Q2 was 17.85 Million DKK , down 0.0% from previous quarter.
Orphazyme A/S reported annual total assets of 56.82 Million DKK in 2022, down -67.2% from previous year.
Orphazyme A/S reported annual total assets of 173.22 Million DKK in 2021, down -78.94% from previous year.
Orphazyme A/S reported quarterly total assets of 17.85 Million DKK for 2024 Q1, down -7.57% from previous quarter.
Orphazyme A/S reported quarterly total assets of 36.18 Million DKK for 2023 Q2, down 0.0% from previous quarter.

Annual Total Assets Chart of Orphazyme A/S (2023 - 2013)

Historical Annual Total Assets of Orphazyme A/S (2023 - 2013)

Year	Total Assets	Total Assets Growth
2023	19.31 Million DKK	-66.02%
2022	56.82 Million DKK	-67.2%
2021	173.22 Million DKK	-78.94%
2020	822.49 Million DKK	355.03%
2019	180.75 Million DKK	-59.05%
2018	441.34 Million DKK	-33.41%
2017	662.81 Million DKK	1975.13%
2016	31.94 Million DKK	-62.4%
2015	84.95 Million DKK	-10.9%
2014	95.34 Million DKK	168.1%
2013	35.56 Million DKK	0.0%

Year	Total Assets	Total Assets Growth
2024 Q2	17.85 Million DKK	0.0%
2024 Q1	17.85 Million DKK	-7.57%
2023 Q2	36.18 Million DKK	0.0%
2023 Q3	19.31 Million DKK	-46.62%
2023 FY	19.31 Million DKK	-66.02%
2023 Q1	36.18 Million DKK	-37.75%
2023 Q4	19.31 Million DKK	0.0%
2022 Q4	58.12 Million DKK	2.28%
2022 Q3	56.82 Million DKK	-39.28%
2022 FY	56.82 Million DKK	-67.2%
2022 Q2	93.58 Million DKK	0.0%
2022 Q1	93.58 Million DKK	-45.97%
2021 Q3	173.22 Million DKK	-59.53%
2021 FY	173.22 Million DKK	-78.94%
2021 Q1	428.03 Million DKK	-47.96%
2021 Q2	428.03 Million DKK	0.0%
2021 Q4	173.22 Million DKK	0.0%
2020 Q2	676.36 Million DKK	0.0%
2020 FY	822.49 Million DKK	355.03%
2020 Q4	822.49 Million DKK	0.0%
2020 Q3	822.49 Million DKK	21.61%
2020 Q1	676.36 Million DKK	274.19%
2019 FY	180.75 Million DKK	-59.05%
2019 Q1	278.92 Million DKK	-36.8%
2019 Q3	180.75 Million DKK	-35.2%
2019 Q4	180.75 Million DKK	0.0%
2019 Q2	278.92 Million DKK	0.0%
2018 Q4	441.34 Million DKK	0.0%
2018 FY	441.34 Million DKK	-33.41%
2018 Q1	544.37 Million DKK	-17.87%
2018 Q2	544.37 Million DKK	0.0%
2018 Q3	441.34 Million DKK	-18.93%
2017 Q2	145.71 Million DKK	0.0%
2017 FY	662.81 Million DKK	1975.13%
2017 Q4	662.81 Million DKK	0.0%
2017 Q3	662.81 Million DKK	354.88%
2017 Q1	145.71 Million DKK	356.19%
2016 Q3	31.94 Million DKK	0.0%
2016 Q4	31.94 Million DKK	0.0%
2016 Q1	- DKK	0.0%
2016 FY	31.94 Million DKK	-62.4%
2015 FY	84.95 Million DKK	-10.9%
2014 FY	95.34 Million DKK	168.1%
2013 FY	35.56 Million DKK	0.0%

Peer Total Assets Comparison of Orphazyme A/S

Name	Total Assets	Total Assets Difference
ALK-Abelló A/S	6.72 Billion DKK	99.713%
Bavarian Nordic A/S	14.35 Billion DKK	99.865%
Genmab A/S	35.28 Billion DKK	99.945%
Gubra A/S	625.28 Million DKK	96.911%
Novo Nordisk A/S	314.48 Billion DKK	99.994%
Pharma Equity Group A/S	81.33 Million DKK	76.256%
Zealand Pharma A/S	3.19 Billion DKK	99.396%